Myleene Klass reveals she helped saved a stranger's life while volunteering with St John's Ambulance at Brighton Pride
The presenter 47, who has been an ambassador for the charity since March 2021, stepped in to help when a man became critically ill during the Sugababes' headline set at Preston Park.
Myleene was part of a first response unit at the festival as had to perform a procedure called a 'jaw thrust' as part of her duties.
A jaw thrust is a manual technique that involves lifting the lower jaw forward to displace the tongue, thus helping to clear the patient's airway.
Taking to Instagram on Monday following the incident, Myleene filmed herself as she heaped praise on the charity, telling how she was 'utterly blown away' she was by everybody's efforts.
She told the camera: 'You can probably hear the Sugababes are on in the background, and I've just helped save a life.
'It was honestly awe-inspiring seeing how St John Ambulance operated. We have doctors and paramedics. Everyone is here. Everyone just did their bit."
The presenter 47, who has been an ambassador for the charity since March 2021, stepped in to help when a man became critically ill during the Sugababes' headline set at Preston Park
Myleene, who has worked on and off with St John's Ambulance since being involved in their 2021 'Ask Me' brand campaign, went on to say that the man had en taken to hospital but she couldn't give any more details.
She said: 'I cannot divulge what happened with the patient, what the circumstances are but what I can say is I am utterly blown away and just to have been a small part of it as well.
'I actually just had to do the procedure that is known as a jaw thrust - that gives you an indication as to how serious the scenario was. The patient is on their way to the hospital right now.'
As part of her caption, Myleene hailed St. John's Ambulance for their work, writing: 'To the SJA team, you are exceptional. You said afterwards you were 'just doing your jobs' but as SJA volunteers, that's not entirely true.
'You were following a calling on your 'day off' which saved a life and immeasurable heartache for the patient's family and friends.'
This isn't the only time Myleene has come to the rescue and saved a life, having saved both of her daughters from choking in the past.
In her 2022 book They Don't Teach This At School, the radio presenter recalled the moment she was caught off-guard when her daughter Ava, 17, choked on calamari while on holiday.
While her youngest girl Hero, 13, got a plastic star stuck in her throat when she was 18 months old.
As part of her caption, Myleene hailed St. John's Ambulance for their work, writing: 'To the SJA team, you are exceptional
She wrote in her book: 'A couple of years ago we were relaxing on holiday and my defences were down, so when Ava started to choke on calamari I didn't immediately realise.
'Hero choked on a small plastic star when she was one and a half.'
The Smooth Radio host went on to describe the mechanics of what to do if someone is choking, and even shared a step-by-step guide to performing CPR.
She previously said of her eldest daughter's incident on social media: 'My daughter (the other one this time) choked on holiday and I only knew what to do because I've done a first aid course.
'Please parents, arm and educate yourselves. It happened so quickly. Five mins later it was as if nothing had happened. I've just booked another refresher course.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
20 minutes ago
- BBC News
Newcastle University kidney drug research 'may be life-changing'
Early withdrawal of a treatment for people with a rare kidney disease is possible without relapse, safer for patients and saves the NHS millions of pounds, researchers Haemolytic Uraemic Syndrome (aHUS) is a life-threatening condition caused by an uncommon defect in the immune system which, in the past, led to kidney failure.A study by Newcastle University has found most patients can stop taking the drug eculizumab after six months and their disease will not return. Prof Neil Sheerin, who led the study, said the findings had "the potential to significantly change the way we manage aHUS and this may be life-changing for some patients". Ending the use of the drug after six months could lead to NHS savings of £4.2m per patient over their lifetime, the university chiefs previously recommended patients stay on eculizumab for the rest of their lives although that leads to an increased risk of meningococcal sepsis. 'I feel like myself again' Twenty-eight people, aged two to 59, from England and Scotland and who had been on eculizumab for at least six months, took part in the patients had their treatment withdrawn. Only four participants' kidney disease returned and the remaining 24 have remained aHus-free to date, the university those taking part was Louise Percival, of York, who was diagnosed with aHus in 35-year-old said she had suffered several side effects, such as migraines, hair loss and breathlessness, before being taken off eculizumab during the described the findings as fantastic."When I was diagnosed with aHUS I felt overwhelmed as it was a huge burden to live with," she said. "It was life-changing as it's something that will never go away."I strongly disliked the eculizumab infusions as they had to be given religiously every two weeks, which impacted my holidays and social events."I'm a very active person, enjoying hiking and the gym, so the side effects and time needed for the treatment were detrimental to my quality of life."I have a fear of needles, so having a cannula put in my arm every fortnight was very distressing."All of the side effects disappeared and I feel like myself again." Prof Sheerin said when a patient initially started treatment for aHUS "they faced a lifetime of eculizumab and the dangers associated with it"."Now we have shown that many people can stop the treatment, freeing them from the burden of regular intravenous injections and removing risk of serious infection associated with the drug," he said."In addition, significant efficiency savings for the NHS of £110.4m over five years could be realised in this patient population through more targeted use of this high-cost treatment."The study was funded by the National Institute for Health and Care Research and published in The Lancet Regional Health Europe. Follow BBC North East on X, Facebook, Nextdoor and Instagram.
Daily Mail
20 minutes ago
- Daily Mail
Warning issued as Britain's 'most dangerous spider' with 'unbearable' bites invades homes across the UK
A stark warning has been issued as Britain's 'most dangerous spider' with an 'unbearable' bite, is about to invade homes across the UK. False Widow spiders are set to appear in greater numbers as spider mating season is set to begin later on in August. This is prompting experts to urge people to keep windows closed both day and night. The venomous animal delivers a bite that, although not lethal, can cause swelling, painful burns and even fever. It is the largest of the three false widow species commonly found near homes. Dr Tom Elwood said as 'spider season' kicked off this month - when horny males move indoors to search for mates - the eight-legged critters could scuttle through pipes into homes. The arachnologist said: 'August is when male spiders become active - they're searching for a mate and they'll wander through open windows, up walls, into bathtubs - anywhere they can.' It comes after Dr Elwood this week urged Brits to clean their windows to stop grimy, cobwebbed frames becoming a haven for the poisonous arachnids. Dr Elwood encouraged Brits to keep their bathtubs, sinks and other areas of their homes clean and tidy to hold back the invasion of venomous critters. He said: 'Spiders are drawn to dust, insect remains and debris.' He added: 'Spiders are already on the move. You may not see them, but they're out there, climbing walls, slipping in through vents and squeezing through the tiniest cracks.' The noble false widow is 'widely regarded as the most dangerous spider breeding in Britain,' according to a 2020 paper by Clive Hambler, an Oxford University zoologist. Known as Steatoda nobilis, they're not native to Britain and are thought to have arrived from the Canary Islands in banana boxes in the late 1800s before slowly spreading northwards. The Daily Mail previously reported that a man believes he was bitten by this spider left him in 'unbearable' pain and struggling to walk. Keith Robinson, 65, says he developed a large, angry inflammation on his leg shortly after clearing out cobwebs at home. At first, he tried to treat it himself using painkillers and savlon, but before long, it became too much to bear and he went to the hospital. Now he's been diagnosed with cellulitis around the wound, and can only walk for short distances before 'intense pain' sets in. He said: 'It must be more than a coincidence that I had removed a large number of cobwebs from the house by hoover. 'So I'm thinking that I've disturbed a spider, and at some point, I got bitten.' The bite, unnoticeable at first, only got worse as the days passed. ARACHNOPHOBIA IS IN OUR DNA Dating back hundreds of thousands of years, the instinct to avoid arachnids developed as an evolutionary response to a dangerous threat, the academics suggest. It could mean that arachnophobia, one of the most crippling of phobias, represents a finely tuned survival instinct. And it could date back to early human evolution in Africa, where spiders with very strong venom have existed millions of years ago. Study leader Joshua New, of Columbia University in New York, said: 'A number of spider species with potent, vertebrate specific venoms populated Africa long before hominoids and have co-existed there for tens of millions of years.
The Sun
20 minutes ago
- The Sun
Brits fast-tracked onto NHS trial of ‘game-changing' cancer vaccine to combat sex-related cases
PEOPLE with head and neck cancer will be given fast-track access to a new "transformative" cancer jab. The injection targets advanced forms of the devastating disease, giving patients "renewed hope of holding it at bay". 2 It works by boosting the immune system's response by using Covid jab-style mRNA technology helping it 'attack' cancer cells containing human papillomavirus (HPV) proteins. Up to 70 per cent of all head and neck cancers are linked to HPV, a virus often spread via sex. This move adds to the NHS England's Cancer Vaccines Launch Pad programme, which has already helped 550 bowel and skin cancer patients. More than 100 patients with advanced head and neck cancer are expected to benefit from the jab through the AHEAD-MERIT (BNT113) trial, running at 15 hospitals over the next year. Head and neck cancer is a general term to describe forms of the disease in those regions of the body, and can include cancer of the mouth, throat or voice box. Around 11,000 new cases are diagnosed in England every year. HPV is a common virus spread through close contact, including sex and childbirth. Most HPV infections clear naturally without causing symptoms. 'Low-risk' types may cause warts, like genital warts or verrucas on hands and feet. But at least 14 'high-risk' types can sometimes trigger cancer. Rock star devastated as he's diagnosed with 'very aggressive' cancer and shares snap from hospital bed Despite treatment advances, aggressive head and neck cancers remain tough to beat, with high recurrence rates and less than 50 per cent surviving beyond two years. The vaccine used in the study has been designed to create two proteins that are commonly found in head and neck cancers associated with high-risk types of HPV. These types of cancer, known as squamous cell cancers, develop from flat, scale-like cells in the outer layer of the skin and other areas of the body. Health minister Karin Smyth described the plan as a "massive win for cancer patients". She added: "These cancer vaccines could be game-changing for patients facing some of the most challenging diagnoses. "By getting these trials running in our NHS, we're putting ourselves at the forefront of medical innovation, improving outcomes for people living with cancer." NHS England has joined forces with life sciences company BioNTech to help identify potentially eligible patients to refer to NHS hospitals running the trial. 2 The trial is the third to be run through the NHS Cancer Vaccine Launch Pad, which is supported by the Cancer Research UK-funded Southampton Clinical Trials Unit. Professor Peter Johnson, national clinical director for cancer at NHS England, said: "It's fantastic that more patients with advanced head and neck cancers will now be able to access this potentially transformative vaccine, offering renewed hope of holding the disease at bay." Tamara Kahn, chief executive at Oracle Head & Neck Cancer UK, said the trial "offers crucial hope to those living with advanced stages of cancer". "While we advocate for HPV vaccination to prevent these cancers, those already fighting this devastating disease urgently need new treatments that could mean more time with loved ones," she added. 'It'll allow people to get on with their lives' Chris Curtis was diagnosed with HPV-related head and neck cancer in 2011 and set up a support charity, The Swallows. The 67-year-old, from Blackpool, said: "As a survivor of HPV-related head and neck cancer, I know first-hand the physical, emotional, and psychological toll this disease takes not just on the patient, but on the entire support system around them. "With this aggressive cancer you live in the fear of reoccurrence every day - so anything that could help control the disease or give people peace of mind is groundbreaking - it'll allow people to get on with their lives and move forward." The Cancer Vaccine Launch Pad - a partnership between NHS England, the Government and BioNTech - has already helped refer about 550 patients to trials for vaccines for bowel and skin cancers. Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: "The Cancer Vaccines Launch Pad is an important route to fast-track promising mRNA vaccine technology into clinical trials. "Research into personalised cancer treatments is vital. "There are over 200 different types of cancer and it's unlikely there will ever be a single cure that works for everyone. "That's why it's vital that we support a wide range of research, so that more people can live longer, better lives, free from the fear of cancer."
